Capital Allocation

Figures converted from renminbi at historical period-end FX rates — see data/company.json.fx_rates. Hong Kong dollar buyback and share-price figures are converted at the HKD/USD rate. Ratios, margins, multiples, percentages and share counts are unitless and unchanged.

Capital Allocation

Meituan has returned cash to shareholders only through buybacks, never a dividend — and the record shows consistent intent but poor timing. It spent about $3.6 billion repurchasing stock across 2024 at an average near $13.9, then all but stopped in 2025 as the price fell below $10 [1] [2]. In the same year it pivoted from returning capital to consuming it. The founders hold roughly a tenth of the equity but control about half the vote. Financials are reported in renminbi and converted here to US dollars, as are the Hong Kong dollar buyback figures; the shares trade in Hong Kong dollars.

Buybacks, never a dividend

Meituan has never paid a dividend. The board declined to recommend one again for 2025, as it has in every year since listing [3]. The single channel it has used to return capital is the share buyback, and it opened that channel only in 2024. Through 2022 and 2023 it repurchased nothing; in 2024 it bought back 261.4 million Class B shares for $3.6 billion; in 2025 it bought back 3.0 million shares for $50 million and cancelled them [4] [5].

Sources: FY2024 Annual Report [6] and FY2025 Annual Report [7]; current price $10.3 per the price history cited in What the Price Implies.

The timing is the problem. The 2024 purchases ran from January to September, and all but the first tranche were bought above $12.5 — the June and July tranches, $2.1 billion of the total, at $13.5 to $15.5, and the September tranche as high as $18.47. The one cheap tranche, January's $8.8–9.9, was the smallest of the large buys. Then in 2025, with the stock cheaper, the program did not scale up to meet it; the only purchase was a $50 million lot in May at $16–17, and nothing at all as the price sank toward $10.

Source: FY2024 Annual Report, Report of Directors, month-by-month repurchase table [8]; May 2025 tranche per FY2025 Annual Report [9].

This runs against what management said it was doing. On the February 2024 call, as the program began, it framed repurchases as "the preferred way to return capital right now, especially because it believes the stock is undervalued" [10]. By early 2025 the stated aim had narrowed to "continuing share repurchase programs to offset dilution from employee stock plans" [11], and a quarter later to considering repurchases "as a tool for enhancing shareholder returns, depending on market conditions" [12]. The company bought most heavily when it called the stock undervalued above $13, and went quiet once the market handed it a lower price.

A share count that barely moved

For all the money spent, the buyback did not shrink the company. Meituan had 6,135,944,107 shares in issue at the end of 2021 and 6,111,665,005 at the end of 2025 — a reduction of about 24 million shares, or 0.4%, across four years [13] [14]. The $3.6 billion of repurchases was largely absorbed offsetting new shares issued under the employee option and award schemes rather than compounding per-share value.

Share-based compensation is the reason. It ran $0.8 billion in 2025 and $1.1 billion in 2024 [15], and the shares issuable under the schemes during 2024 alone equalled 2.37% of the weighted-average share count [16]. A buyback that keeps the count flat is doing useful work — dilution left unchecked compounds against holders — but it is defence, not return. When repurchases collapsed in 2025 while grants continued, that defence lapsed: the count is now set to drift up again unless the program resumes.

From returning capital to consuming it

2024 and 2025 were opposite years for Meituan's capital account. In 2024 the company was a net returner of capital: financing activities were a $4.2 billion outflow, dominated by the buyback. In 2025 financing flipped to a $3.0 billion inflow, "mainly attributable to the issuance of notes payable and proceeds from borrowings" [17].

Source: FY2025 Annual Report, Consolidated Statement of Cash Flows and MD&A; FY2023 Annual Report for prior years [18].

Four decisions turned the account around. The largest was the choice to fight the subsidy war: selling and marketing expense rose 60.9% to $14.4 billion in 2025, an increase of $5.4 billion that turned Core Local Commerce from profit to loss (The Delivery War) [19]. Alongside it, the company raised debt: in November 2025 it issued five tranches of senior notes — $0.29 billion and $0.70 billion of renminbi-denominated notes plus US$600 million, US$600 million and US$800 million of dollar notes — "primarily for refinancing of existing offshore indebtedness and other general corporate purposes" [20]. It scaled a lending balance sheet, letting the micro-credit loan book roughly double to about $2.7 billion — the largest single use of operating cash in the year (Cash Conversion) [21]. And in February 2026 it agreed to acquire a grocery target for an initial US$717 million, its largest disclosed acquisition in years [22].

None of this threatens the balance sheet — the roughly $12.2 billion of net cash and covenant-free, long-dated debt established in What the Price Implies and Cash Conversion absorb it comfortably. But the character of the capital account changed. A business that in 2024 was buying back its own shares became, in 2025, one funding a price war, a loan book, and an overseas push partly with borrowed money — while its own stock traded below the level at which it had been repurchasing.

Control without a majority

Who makes these calls, and on whose behalf, is set by the share structure. Meituan runs weighted voting rights: each Class A share carries ten votes, each Class B one [23]. Wang Xing, the founder, chairman and chief executive, beneficially owns 515.9 million Class A shares — about 45.3% of the vote — and co-founder Mu Rongjun a further 5.6%, so the two control roughly 51% of the vote [24]. Their combined 579.2 million shares are about 9.5% of the equity. The filing states the point plainly: the beneficiaries "do not hold a majority economic interest in the share capital of the Company" [25].

Alignment and control are not the same thing, and here they pull in different directions. On alignment, the signals are good: Wang Xing takes almost no pay for the control he holds — total 2025 emoluments of $0.7 million, all salary, with no bonus and no new equity grant — so his stake, not his paycheque, is how he is paid [26]. The board carries a four-to-two independent majority with genuinely senior outside directors, and at the 2026 annual meeting the audit committee passed to a former KPMG China chairman. On control, the offsets are thinner: the chairman and chief executive roles are combined in one person, a stated deviation from Hong Kong's governance code that the board defends as "consistent leadership" [27], and the reserved matters on which one-share-one-vote applies are limited to constitutional questions — amending the charter, appointing auditors, removing independent directors, and winding up. Capital allocation is not among them.

There is a disclosure limit worth stating: as a Hong Kong issuer Meituan publishes no ongoing insider-transaction record, so the usual test of whether insiders are buying their own stock in the open market cannot be run here. What can be said is that the founders have not diluted themselves — the 2021 convertible bonds carry a $55.4 conversion price, more than five times the current quote, so they are debt that will not convert into shares [28].

Reading the record

The evidence points to a capable operator whose capital-allocation judgment is the weaker part of the case. The alignment is real and cheaply demonstrated — minimal pay, a large personal stake, no self-dilution — and the dominant 2025 decision, spending a year of Core profit to hold the franchise against two better-funded attackers, is defensible on the logic set out in The Delivery War. The strongest fact against a harsh read is the war itself: JD's February 2025 entry was not knowable when the 2024 buyback was running, and a company facing an unforeseen price war was right to preserve cash rather than keep repurchasing into it. Buying back stock while burning $3.8 billion of free cash flow would have been the greater error.

What the record does not support is the idea that management repurchases with discipline. It bought $3.6 billion of stock at an average near $13.9, most of it above $13 while calling the shares undervalued, and then declined to buy when the market offered the same shares below $10. That is the opposite order from value-accretive repurchase, and it is the clearest evidence in the file of imperfect market judgment steering a balance sheet that the founders control outright.

The read would change with the next capital return. A buyback resumed at scale now — with the trough passing, the Q1 2026 recovery underway, and the stock near $10 — would show the 2024 timing was circumstance rather than habit, and would offset the dilution now running unchecked. Continued quiet on repurchases, with the freed cash flowing instead into the loan book, overseas expansion and acquisitions, would confirm a management that prefers building the company to compounding its shares — a preference minority holders, who own most of the equity but little of the vote, can do little about.